CD163 and triple-negative breast carcinoma: Indeed, some authors have described an improved survival of ER- or triple-negative breast cancer (TNBC) patients with a CD163+CD68+ macrophage infiltrate (10), while others correlated the presence of tumor-infiltrating CD163+ macrophages with a worse prognosis of TNBC patients (11).